PROZINC DIN 02405202
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Health Canada record
| Active ingredient(s) | INSULIN (HUMAN) 40 UNIT |
|---|
| Dosage form | Suspension |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D |
|---|
| Class | Veterinary |
|---|
| ATC | |
|---|
| Original market date | 04-Nov-2013 |
|---|
| Current status date | 28-Feb-2020 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing INSULIN (HUMAN)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02529602 | MYXREDLIN | BAXTER CORPORATION | Solution | INSULIN (HUMAN) 1 UNIT | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 23263 | 2020-02-28 | New Drug Submission (NDS) | Administrative - Change in Product Ownership |
| 22022 | 2019-03-29 | Supplement to a New Drug Submission (SNDS) | New species: dogs |
| 14312 | 2013-04-24 | New Drug Submission (NDS) | |
Request a quote for PROZINC
How to read a Canadian DIN record